EXPANDED ACCESS PROGRAM
At Keymed, we are committed to developing products that bring new, innovative therapies to patients, such as CMG901.
At this time, Keymed does not offer an expanded access program and is not accepting expanded access requests for investigational products, such as CMG901. Keymed’ current focus and priority is to complete the product development program for its investigational products, such as CMG901, to obtain the required safety and efficacy data needed for regulatory approval. We believe that focusing our resources on our clinical trial programs is the best path forward to bring our investigational products to patients as quickly and safely as possible. Patients may gain access to our clinical-stage investigational products, such as CMG901, by participating in our clinical trials. If you would like to learn more about Keymed’ clinical trials, please view the links above within .
As we continue to develop investigational products, we will review our expanded access policy for investigational products and may make updates to this policy. For more information about expanded access in the U.S., please visit the FDA website at .
Company Profile Management Team Milestones Corporate Culture
R&D Center Pipeline Manufacturing Park Cooperation Expanded Access Policy
Corporate Governance Information Disclosure Financial Reports Stock Information IR Calendar Investor Presentations Email Alerts
Latest News Media
Culture & Benefits
Contact Information Consultation Legal Statement Privacy